Publications

The aims of this study were to compare clinical and psychosocial parameters between patients with a different severity of atopic dermatitis and to analyse the effect of an omega-6-fatty-acid-skin therapy.

Oral presentation presented at the 23^rd DKVF Conference, Potsdam, Germany

Oral presentation presented at the European Health Psychology Society Conference (EHPS), Cascais, Portugal

Oral presentation presented at the 10^th Appearance Matters Conference, Bristol, UK

Poster presented at the 33rd EADV Congress, Amsterdam, the Netherlands

Poster presented at the 52. Jahrestagung der Deutschen Dermatologischen Gesellschaft (DDG-Tagung), Berlin, Germany.

Oral presentation presented at the 25th World Congress of Dermatology, Singapore

Oral presentation presented at the 25th World Congress of Dermatology, Singapore

Psoriasis is a chronic inflammatory skin disease that negatively impacts the quality of life of patients and their families. However, the most commonly used decision-making tools in psoriasis, Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA) and Dermatology Life Quality Index (DLQI), do not fully capture the impact of psoriasis on patients' lives. In contrast, the well-established 5-item WHO Well-being Index (WHO-5) assesses the subjective psychological well-being of patients. Moreover, while drug innovations became available for psoriasis, data on the impact of these therapies on patients' lives and their closest environment (family, physicians) are limited. This study will assess the effect of tildrakizumab, an interleukin-23p19 inhibitor, on the overall well-being of patients with moderate-to-severe psoriasis. Moreover, the long-term benefit of tildrakizumab on physicians' satisfaction and partners' lives of patients with psoriasis will be evaluated.

Oral presentation presented at the 25th World Congress of Dermatology, Singapore